Trial Profile
Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer
- Focus Therapeutic Use
- 03 Nov 2016 Status changed from recruiting to completed.
- 30 Sep 2014 New trial record